The elimination of generic drugs intensified, and a large number of pharmaceutical companies withdrew from the market

"Pharmaceutical network industry dynamics" recently, Shanxi Province pharmaceutical procurement centralized bidding procurement platform issued two consecutive notices, Zhengda Youth Bao Pharmaceutical Co., Ltd., Jilin One Zheng Pharmaceutical Group Co., Ltd. a total of 14 pharmaceutical companies 18 drugs, apply to withdraw the centralized procurement of the winning product platform hanging network qualification, enterprises provide a national unified commitment not to supply.
fact, pharmaceutical enterprises actively apply for product revocation of the internet, is a common phenomenon in the pharmaceutical industry in recent years. Today, April 23,
, Hainan Province Public Resources Trading Service Center issued "on the publicity of the part of the new hanging and withdrawal of drug information notice", the notice mentioned that Awei acid pyridexole tablets, quepibton tablets, lithium carbonate tablets, heparin sodium injection, hydrochloric acid bubika injection 5 drugs due to rising costs, apply for removal of the network.
May 21, Shandong Province Public Resources Trading Center issued the "Notice on the publicity of partial withdrawal of drug information (third batch in 2020)," 44 drug withdrawal network, involving a total of 36 varieties, respectively, from 34 pharmaceutical production enterprises.
Among them, there are well-known enterprise varieties, such as Jiangsu Hausen Pharmaceuticals' Reglinai tablets (size: 0.5mg), Guilin Sanjin Pharmaceuticals' compound gastric pain capsules (specs: 0.5g), Zhejiang Haizheng Pharmaceuticals' sulfate glucose capsules (specs: 0.25g), Yangzijiang Pharmaceuticals' hydrochloric acid left oxyfluorosa star capsules (specs: 0.1g) and so on.
In addition to the above-mentioned provinces and cities, Hainan, Sichuan, Fujian, Zhejiang, Gansu and other provinces this year have also appeared in the drug companies to voluntarily scrap the bid or withdraw the situation, some provinces and cities even appeared many times.
data show that so far, enterprises have voluntarily applied for the removal of thousands of drugs.
is worth noting that pharmaceutical companies hang up the network and then withdraw the label, which means that pharmaceutical companies have chosen to scrap the label.
understood that once the drug scrapping, the withdrawal of the network means that will exit the market, lost the original market share.
In addition, in accordance with the relevant rules of tendering and credit management, these production enterprises may also be included in the list of unperforming enterprises, and other provinces may abandon such enterprises, these enterprises will continue to participate in the bidding opportunities will become very slim.
why do companies risk being included in bad records and exit the market? Industry insiders say that enterprises to withdraw from the market is also a last-order.
recent years, drug raw materials and production costs have been rising year by year, as well as by the impact of policies such as volume procurement, resulting in many drug prices fell again and again.
under the influence of dual factors, resulting in the pharmaceutical companies profits are meager or even can not make money at all, so many pharmaceutical companies have to bear the pain of abandoning the bid, withdrawal of the network, or even stop production.
although it is said that after many varieties exited the public hospital market, most of them turned to the retail market, but in recent years, retail pharmacies and other drug prices are also in the same price, unlimited pressure.
means that in the future only through rebates to do the market products will have no way to go, pharmaceutical representatives and agents can only take the initiative to accelerate the transformation.
addition, the future drug sales channels can not control the enterprise, the cost can not meet the national bid price requirements of enterprises, is also destined to be eliminated.
, even as many pharmaceutical companies have opted out of the market, a large number of agents and pharmaceutical representatives are being cleared.
In recent years, not only have many streaming companies cut sales staff, but many of the winning drug companies' sales models have also been changed by volume purchases, such as Sanofi's hydrochlorochloropolyte tablets (Polyvi) being revealed to have disbanded medical and sales teams after being shortlisted.
industry said that with the continuous expansion of volume procurement, pharmaceutical companies to lay off workers, the company's restructuring will be more and more concentrated outbreak.
, in the context of medical reform, the test facing pharmaceutical companies is huge, not only to bear the trend of falling drug prices, but also to strictly control the quality of drugs.
some enterprises risk default, breach of trust, the risk of being abandoned scrapping the standard, it is helpless.
for the rest of the enterprises, many leading pharmaceutical companies because of adequate funds, complete technology has long chosen a good path of innovation;